Fig. 4

EP300 KD reduces cell metastatic colonization and circulating tumor cells in vivo. a, Scratch or wound healing assay comparing MDA-MB-231 scramble transfected and EP300 KD clones (n = 6 per cell line). b, In vivo bioluminescence images of mice bearing xenografts of MDA-MB-231^Scramble and EP300 KD (clone 1 and 2) 5 weeks after tail vein injection (n = 4 for scramble, n = 5 for EP300 KD clones each). c, Quantification of bioluminescence measurements (post 5 weeks). d, Survival curve for mice injected via the tail vein with MDA-MB-231^Scramble or EP300 KD. e, Circulating tumor cell quantification based on GFP expression via FACS in peripheral blood of mice post tail vein injection with MDA-MB-231^Scramble or EP300 KD cells (same mice as shown in d). (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)